Attenuation of thermal nociception and hyperalgesia by VR1 blockers
- 19 February 2002
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 99 (4) , 2374-2379
- https://doi.org/10.1073/pnas.022285899
Abstract
Vanilloid receptor subunit 1 (VR1) appears to play a critical role in the transduction of noxious chemical and thermal stimuli by sensory nerve endings in peripheral tissues. Thus, VR1 antagonists are useful compounds to unravel the contribution of this receptor to pain perception, as well as to induce analgesia. We have used a combinatorial approach to identify new, nonpeptidic channel blockers of VR1. Screening of a library of trimers of N -alkylglycines resulted in the identification of two molecules referred to as DD161515 { N -[2-(2-( N -methylpyrrolidinyl)ethyl]glycyl]-[ N -[2,4-dichlorophenethyl]glycyl]- N -(2,4-dichlorophenethyl)glycinamide} and DD191515 {[ N -[3-( N , N -diethylamino)propyl]glycyl]-[ N -[2,4-dichlorophenethyl]glycyl]- N -(2,4-dichlorophenethyl)glycinamide} that selectively block VR1 channel activity with micromolar efficacy, rivaling that characteristic of vanilloid-related inhibitors. These compounds appear to be noncompetitive VR1 antagonists that recognize a receptor site distinct from that of capsaicin. Intraperitoneal administration of both trialkylglycines into mice significantly attenuated thermal nociception as measured in the hot plate test. It is noteworthy that these compounds eliminated pain and neurogenic inflammation evoked by intradermal injection of capsaicin into the animal hindpaw, as well as the thermal hyperalgesia induced by tissue irritation with nitrogen mustard. In contrast, responses to mechanical stimuli were not modified by either compound. Modulation of sensory nerve fibers excitability appears to underlie the peptoid analgesic activity. Collectively, these results indicate that blockade of VR1 activity attenuates chemical and thermal nociception and hyperalgesia, supporting the tenet that this ionotropic receptor contributes to chemical and thermal sensitivity and pain perception in vivo . These trialkylglycine-based, noncompetitive VR1 antagonists may likely be developed into analgesics to treat inflammatory pain.Keywords
This publication has 29 references indexed in Scilit:
- The Vanilloid Receptor: A Molecular Gateway to the Pain PathwayAnnual Review of Neuroscience, 2001
- Identification of an Aspartic Residue in the P-loop of the Vanilloid Receptor That Modulates Pore PropertiesJournal of Biological Chemistry, 2000
- Can peptides be mimicked?Drug Discovery Today, 2000
- Impaired Nociception and Pain Sensation in Mice Lacking the Capsaicin ReceptorScience, 2000
- Experiments and Simulations of Ion-Enhanced Interfacial Chemistry on Aqueous NaCl AerosolsScience, 2000
- Unsaturated Long-Chain N-Acyl-vanillyl-amides (N-AVAMs): Vanilloid Receptor Ligands That Inhibit Anandamide-Facilitated Transport and Bind to CB1 Cannabinoid ReceptorsBiochemical and Biophysical Research Communications, 1999
- Blood-brain barrier biology and methodologyJournal of NeuroVirology, 1999
- The Cloned Capsaicin Receptor Integrates Multiple Pain-Producing StimuliNeuron, 1998
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews, 1997
- Comparison of the proteolytic susceptibilities of homologous L‐amino acid, D‐amino acid, and N‐substituted glycine peptide and peptoid oligomersDrug Development Research, 1995